Amirthalingam Palanisamy, Alatawi Olayan Salamah, Hamdan Ahmed Mohsen Elsaid, Aljabri Ahmed, Alqifari Saleh, Alshareef Hanan, Hakami Faris Ahmed M, Albalawi Nader Salem, A Albrahimi Hazem Moufeed, Mubark Alanazi Sultan Mohammed, Alatawi Ahmed Mutair, Albalwi Abdullah Abdalziz S, Ali Mostafa A Sayed
Department of Pharmacy Practice, Faculty of Pharmacy, University of Tabuk, Tabuk, Saudi Arabia.
King Salman Armed Forces Hospital, Northwestern Region, Tabuk, Saudi Arabia.
Patient Prefer Adherence. 2025 Aug 20;19:2535-2551. doi: 10.2147/PPA.S534534. eCollection 2025.
Semaglutide, a once-weekly injection (SOWI), is a glucagon-like peptide-1 receptor agonist for managing type-2 diabetes (T2D). However, it has a high discontinuation rate among users in the first year after treatment initiation. This study investigated the medication adherence level among T2D patients managed with SOWI.
This cross-sectional study was conducted among T2D patients aged 18 years or above who visited the outpatient pharmacy to refill their prescriptions for SOWI. The patients responded to their sociodemographic characteristics and the Adherence to Refills and Medications Scale (ARMS). The patient's electronic health record obtained details of the proportion of days covered (PDC), glycosylated hemoglobin (HbA1C), and body mass index (BMI). The association of medication adherence and sociodemographic characteristics, as well as the clinical outcomes between patients with different levels of adherence, were analyzed.
A total of 434 patients were included in this study. According to the ARMS score, only 32.48% (141) of the patients adhered to SOWI. Sociodemographic characteristics had lower odds association for medication non-adherence. However, non-adherent patients had a significant association with BMI (overweight and obese) and HbA1C (>7). The adherence level of PDC for SOWI was significantly associated with the ARMS medication adherence level. The mean HbA1C and BMI between adherents and non-adherents were statistically significant (p<0.001). The patients who adhered to both ARMS and PDC (n = 126) experienced a significant decline in mean BMI (p < 0.001) and HbA1C (p < 0.001) compared to patients who adhered to PDC but not ARMS and those who did not adhere to either ARMS or PDC.
Medication adherence to the SOWI is subjective to T2D patients and not influenced by sociodemographic characteristics. T2D patients need more motivation to refill and administer the SOWI according to the schedule since medication adherence directly impacts HbA1C and BMI.
司美格鲁肽是一种每周注射一次的药物,用于治疗2型糖尿病(T2D)。然而,在开始治疗后的第一年,其停药率较高。本研究调查了接受司美格鲁肽治疗的2型糖尿病患者的用药依从性水平。
本横断面研究在18岁及以上的2型糖尿病患者中进行,这些患者到门诊药房补充司美格鲁肽的处方。患者回答了他们的社会人口学特征以及用药依从性量表(ARMS)。通过患者的电子健康记录获取了用药天数比例(PDC)、糖化血红蛋白(HbA1C)和体重指数(BMI)的详细信息。分析了用药依从性与社会人口学特征之间的关联,以及不同依从性水平患者之间的临床结局。
本研究共纳入434例患者。根据ARMS评分,只有32.48%(141例)的患者坚持使用司美格鲁肽。社会人口学特征与用药不依从的关联几率较低。然而,不依从的患者与BMI(超重和肥胖)及HbA1C(>7)显著相关。司美格鲁肽的PDC依从水平与ARMS用药依从水平显著相关。依从者和不依从者之间的平均HbA1C和BMI在统计学上有显著差异(p<0.001)。与仅坚持PDC但不坚持ARMS的患者以及既不坚持ARMS也不坚持PDC的患者相比,同时坚持ARMS和PDC的患者(n = 126)的平均BMI(p < 0.001)和HbA1C(p < 0.001)显著下降。
2型糖尿病患者对司美格鲁肽的用药依从性是主观的,不受社会人口学特征影响。2型糖尿病患者需要更多动力按照时间表补充和使用司美格鲁肽,因为用药依从性直接影响HbA1C和BMI。